Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT) tra...
Saved in:
Main Authors: | Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon, John L. Barstis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2015-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/3/1/41.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors
by: Xuemei Wang, et al.
Published: (2025-02-01) -
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01) -
Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature
by: Cristina Dumitrescu, et al.
Published: (2013-01-01) -
Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)